At a glance
ClinicalIndex Comparison Record- ✓Breast cancer diagnosis confirmed by biopsy
- ✓Age >18 years
- ✓ECOG performance status 0 or 1
- ✓Normal left ventricular ejection fraction on MUGA scan
- ✕Stage IV breast cancer
- ✕Inflammatory breast cancer
- ✕Locally advanced disease with skin ulcerations
- ✕Brain or CNS metastases
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorubicin in Operable/Locally Advanced Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Bevacizumab, Cyclophosphamide, and 1 other intervention for Breast Cancer. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The main purpose of this study is to find out what effects taking the drug bevacizumab together with two chemotherapeutic agents, docetaxel and cyclophosphamide followed by doxorubicin alone before surgery will on breast cancer. Bevacizumab will be given for twelve weeks in combination with chemotherapy then it ill be held during the administration of doxorubicin. Twenty-eight to fifty-six days after undergoing surgery, all patients will receive nine three-weekly infusions of bevacizumab.
Study Details
Timeline
Interventions
IV 15mg/kg 21 days
500mg per meter squared, IV every 21 days
60 mg per meter squared, IV every 21 days